Pramlintide is a synthetic version of amylin, a hormone that pancreatic beta cells release alongside insulin every time you eat. Native human amylin clumps together and is hard to formulate as a drug. Chemists fixed that by swapping in three proline residues at positions 25, 28 and 29, which stops the peptide from self-aggregating. The result is pramlintide, sold as Symlin (pramlintide acetate) and known in older literature by codes like AC-137, AC-0137 and tripro-amylin.
The US Food and Drug Administration approved it in 2005 as an injectable adjunct to mealtime insulin in people with type 1 or type 2 diabetes who haven't reached their glucose targets on insulin alone. It is not a substitute for insulin, and it is given as a separate subcutaneous injection at meals.
How it works
Amylin and insulin are co-secreted, so pramlintide adds back a signal that is missing or blunted in diabetes. It binds amylin receptors in the brain, which are calcitonin receptors paired with receptor activity-modifying proteins (RAMP1-3). Through those receptors it does three things at mealtimes, according to DrugBank and review literature:
- Slows gastric emptying, so glucose from a meal enters the bloodstream more gradually without changing how much is ultimately absorbed.
- Suppresses postprandial glucagon, the hormone that would otherwise push the liver to release more glucose after eating.
- Increases satiety, which tends to reduce how much people eat.
Together these blunt the spike in blood sugar after a meal, an effect that mealtime insulin alone handles imperfectly.
What the clinical research found
The diabetes evidence is real and goes back decades. An early double-blind, placebo-controlled crossover trial in Metabolism (1999) gave 14 type 1 patients 30 micrograms four times daily for four weeks. Serum fructosamine fell (314 vs 350 micromol/L, P = .008), mean plasma glucose dropped, and peak glucagon 60 minutes after breakfast was roughly a third lower on pramlintide (Nyholm et al., PubMed). A later systematic review and meta-analysis of pramlintide added to insulin in type 1 diabetes found modest reductions in HbA1c and body weight alongside lower insulin requirements.
More recent work has tested pramlintide inside closed-loop (artificial pancreas) systems. Co-administering it with insulin delayed the time to peak post-meal glucose and shrank the size of the glucose excursion in adolescents and young adults (Weinzimer et al., PubMed).
The weight-loss angle is where pramlintide matters most for the current peptide moment. It does cause modest weight loss, but its low potency limits it. That limitation is exactly why the newer, more potent amylin agonists like cagrilintide and eloralintide are being developed for obesity. Pramlintide is, in effect, the proof-of-concept that put amylin on the obesity map.
Safety and regulatory status
Symlin carries an FDA boxed warning for severe insulin-induced hypoglycemia, which tends to happen within three hours of an injection and can cause serious injury if it occurs while driving or operating machinery. Because of that risk, mealtime insulin doses are usually cut when pramlintide is started. The most common side effects reported in trials were nausea, vomiting and reduced appetite, which generally eased over time.
For anti-doping purposes, pramlintide is not specifically named on the WADA Prohibited List; anyone subject to testing should confirm current status directly with WADA or their sport's authority rather than rely on a general article.
The quality angle for buyers
Pramlintide as Symlin is a prescription drug dispensed through pharmacies. Material sold online as a "research peptide" is a different thing entirely: it is not the FDA-approved product, is labeled research-use-only, and is not intended for human consumption. Unregulated peptide vials vary in purity and identity, and the only way to know what is actually in one is a third-party certificate of analysis covering identity (typically mass spec) and purity (typically HPLC). peptideone aggregates the independent purity and reputation signals that vendors and labs publish so those claims can be compared, but no COA changes the fact that this compound's approved use is a physician-supervised prescription.
Nothing here is medical or dosing advice. The numbers and mechanisms above come from the cited sources, not from us.